Skip to main content
Methotrexate in Psoriasis and Psoriatic Arthritis.
The Journal of rheumatology. Supplement
  • Laura C Coates
  • Joseph F Merola
  • Suzanne M Grieb
  • Philip Mease, Providence St. Joseph Health
  • Kristina Callis Duffin
Document Type
Publication Date

Methotrexate (MTX) is the most commonly prescribed first-line therapy in psoriatic arthritis (PsA) internationally and is also commonly used in the treatment of psoriasis. However, data supporting its use in PsA are limited and significant toxicities can occur. This article summarizes a debate at the 2019 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting that focused on the use of MTX in psoriasis and PsA. Four clinicians and 1 patient research partner presented clinical study data and the patient experience summarizing the efficacy, tolerability, and toxicity of MTX for both skin and musculoskeletal manifestations. A survey of attending GRAPPA members collected data on current and planned future use of MTX across the world.

Clinical Institute
Orthopedics & Sports Medicine
Citation Information
Laura C Coates, Joseph F Merola, Suzanne M Grieb, Philip Mease, et al.. "Methotrexate in Psoriasis and Psoriatic Arthritis." The Journal of rheumatology. Supplement (2020)
Available at: